论文部分内容阅读
目的对比亚胺培南西司他丁钠与莫西沙星治疗重症社区获得性肺炎(SCAP)的疗效及经济学差异。方法将94例SCAP患者按随机数字表法分为对照组和观察组各47例,两组均给予常规对症治疗,抗菌药物对照组选用莫西沙星,观察组选用亚胺培南西司他丁钠,对比两组疗效及药物经济学。结果观察组总有效率94.49%优于对照组的76.59%,治疗成本高于对照组,住院时间、成本-效果比均低于对照组,差异均有统计学意义(P<0.05)。结论亚胺培南西司他丁钠治疗SCAP较莫西沙星疗效佳、预后好,具有更好的经济学优势。
Objective To compare the efficacy and economic differences between imipenem, cilastatin sodium and moxifloxacin in the treatment of severe community acquired pneumonia (SCAP). Methods Ninety-four SCAP patients were divided into control group and observation group according to random number table method, 47 cases in each group were given conventional symptomatic treatment, moxifloxacin in antibacterial drug control group, imipenem cilastatin sodium in observation group , Comparing two groups efficacy and pharmacoeconomics. Results The total effective rate in the observation group was 94.49%, which was significantly higher than that in the control group (76.59%). The treatment cost was higher than that in the control group, and the hospitalization time and cost-effectiveness ratio were all lower than those in the control group (P <0.05). Conclusion Imipenem and cilastatin sodium has better curative effect and better prognosis than moxifloxacin, which has better economic advantages.